The Microbiome and Uveitis : A Narrative Review
Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved..
The human intestinal microbiome is composed of hundreds of species and has recently been recognized as an important source of immune homeostasis. While dysbiosis, an altered microbiome from the normal core microbiome, has been associated with both intestinal and extraintestinal autoimmune disorders, including uveitis, causality has been difficult to establish. There are four proposed mechanisms of how the gut microbiome may influence the development of uveitis: molecular mimicry, imbalance of regulatory and effector T cells, increased intestinal permeability, and loss of intestinal metabolites. This review summarizes current literature on both animal and human studies that establish the link between dysbiosis and the development of uveitis, as well as provides evidence for the above mechanisms. Current studies provide valuable mechanistic insights as well as identify potential therapeutic targets. However, study limitations and the wide variability in the intestinal microbiome among populations and diseases make a specific targeted therapy difficult to establish. Further longitudinal clinical studies are required to identify any potential therapeutic that targets the intestinal microbiome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:193 |
|---|---|
| Enthalten in: |
The American journal of pathology - 193(2023), 11 vom: 01. Nov., Seite 1638-1647 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Janetos, Timothy M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ajpath.2023.03.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355287129 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355287129 | ||
| 003 | DE-627 | ||
| 005 | 20231226064030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajpath.2023.03.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355287129 | ||
| 035 | |a (NLM)37024044 | ||
| 035 | |a (PII)S0002-9440(23)00115-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Janetos, Timothy M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Microbiome and Uveitis |b A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The human intestinal microbiome is composed of hundreds of species and has recently been recognized as an important source of immune homeostasis. While dysbiosis, an altered microbiome from the normal core microbiome, has been associated with both intestinal and extraintestinal autoimmune disorders, including uveitis, causality has been difficult to establish. There are four proposed mechanisms of how the gut microbiome may influence the development of uveitis: molecular mimicry, imbalance of regulatory and effector T cells, increased intestinal permeability, and loss of intestinal metabolites. This review summarizes current literature on both animal and human studies that establish the link between dysbiosis and the development of uveitis, as well as provides evidence for the above mechanisms. Current studies provide valuable mechanistic insights as well as identify potential therapeutic targets. However, study limitations and the wide variability in the intestinal microbiome among populations and diseases make a specific targeted therapy difficult to establish. Further longitudinal clinical studies are required to identify any potential therapeutic that targets the intestinal microbiome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Zakaria, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Debra A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of pathology |d 1925 |g 193(2023), 11 vom: 01. Nov., Seite 1638-1647 |w (DE-627)NLM000077895 |x 1525-2191 |7 nnns |
| 773 | 1 | 8 | |g volume:193 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:1638-1647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajpath.2023.03.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 193 |j 2023 |e 11 |b 01 |c 11 |h 1638-1647 | ||